Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.

Authors

Nathan A. Pennell

Cleveland Clinic, Cleveland, OH

Nathan A. Pennell , Alex Mutebi , Zheng-Yi Zhou , Marie Louise Ricculli , Wenxi Tang , Helen Wang , Annie Guerin , Tom Arnhart , Kenneth W. Culver , Gregory Alan Otterson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).

First Author: John Leonard Fox

insert_chart_outlined

Poster

2020 ASCO Quality Care Symposium

bookmark_border

Biomarker testing patterns and use of targeted therapy in Medicare Fee-for-Service (FFS) beneficiaries newly diagnosed with metastatic non-small cell lung cancer (mNSCLC).

First Author: Anik Patel

insert_chart_outlined

Poster

2023 ASCO Quality Care Symposium

bookmark_border

Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).

First Author: Ruchit Shah

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.

First Author: Aurélie Swalduz